1. Home
  2. AGMH vs VRAX Comparison

AGMH vs VRAX Comparison

Compare AGMH & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AGM Group Holdings Inc.

AGMH

AGM Group Holdings Inc.

N/A

Current Price

$0.60

Market Cap

2.5M

Sector

Technology

ML Signal

N/A

VRAX

Virax Biolabs Group Limited

N/A

Current Price

$1.89

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AGMH
VRAX
Founded
2015
2013
Country
Hong Kong
United Kingdom
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5M
2.1M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
AGMH
VRAX
Price
$0.60
$1.89
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 4.3M
155.8K
Earning Date
10-20-2026
11-20-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.07
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.10
52 Week High
$5.77
$13.19

Technical Indicators

Market Signals
Indicator
AGMH
VRAX
Relative Strength Index (RSI) 34.16 33.40
Support Level $0.48 $0.16
Resistance Level $1.38 $3.01
Average True Range (ATR) 0.12 0.29
MACD -0.01 -0.03
Stochastic Oscillator 5.44 4.58

Price Performance

Historical Comparison
AGMH
VRAX

About AGMH AGM Group Holdings Inc.

AGM Group Holdings Inc is a technology company engaged in technology hardware research and development, manufacturing, assembly, and sales. Its core business segments include research and development of blockchain-oriented ASIC chips, production of high-end crypto miners for Bitcoin and other cryptocurrencies, and Fintech software services. The Company mainly derives revenue from the sales of cryptocurrency mining machines and standardized computing equipment.

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

Share on Social Networks: